Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients

被引：2
|
作者：
Capria, Saveria [1 ]
Trisolini, Silvia Maria [1 ]
Minotti, Clara [1 ]
Stefanizzi, Caterina [1 ]
Cardarelli, Luisa [1 ]
Canichella, Martina [1 ]
Cartoni, Claudio [1 ]
Diverio, Daniela [1 ]
De Propris, Maria Stefania [1 ]
Mancini, Marco [1 ]
Micozzi, Alessandra [1 ]
Foa, Robin [1 ]
Meloni, Giovanna [1 ]
机构：
[1] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Hematol, Via Benevento 6, I-00161 Rome, Italy
来源：
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES | 2012年 / 4卷 / 01期
关键词：
D O I：
10.4084/MJHID.2012.072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] ARA-C, IDARUBICINE AND GEMTUZUMAB OZOGAMICIN AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
    Capria, S.
    Cardarelli, L.
    Trisolini, S. M.
    Cartoni, C.
    Minotti, C.
    Gianfelici, V
    Arleo, E.
    Santini, L.
    De Propris, M. S.
    Mancini, M.
    Martinelli, G.
    Foa, R.
    Meloni, G.
    HAEMATOLOGICA, 2008, 93 : S84 - S84
  • [2] ID-Ara-C, idarubicine and mylotarg gemtuzumab ozogamicin as salvage treatment in advanced AML patients
    Cardarelli, L.
    Capria, S.
    Trisolini, S. M.
    Cimino, G.
    Diverio, D.
    Guarini, A.
    Mancini, M.
    Martinelli, G.
    Foa, R.
    Meloni, G.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S62 - S62
  • [3] SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Malato, A.
    Santoro, A.
    Felice, R.
    Magrin, S.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2013, 98 : 31 - 31
  • [4] Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
    Erba, H. P.
    Rizzieri, D. A.
    O'Donnell, M. R.
    Lundberg, A. S.
    Ajami, A. M.
    Rampersad, A. D.
    Capizzi, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
    Jain, Preetesh
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Jabbour, Elias
    Daver, Naval
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Alvarado, Yesid
    Jain, Nitin
    Borthakur, Gautam
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Ohanian, Maro
    Konopleva, Marina
    Naqvi, Kiran
    Fitch, Tina
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Estrov, Zeev
    Kadia, Tapan M.
    BLOOD, 2016, 128 (22)
  • [6] ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA
    JAGER, U
    LECHNER, K
    SCHWARZINGER, I
    BETTELHEIM, P
    BOGNAR, H
    GEISSLER, K
    HAAS, O
    HINTERBERGER, W
    KOS, M
    LEITHA, T
    NEUMANN, E
    PANZER, S
    POLLAK, C
    BLUT, 1986, 53 (03): : 145 - 145
  • [7] Multicenter phase III trial on fludarabine, Ara-C, and idarubicine (FLAI) versus idarubicine, Ara-C and etoposide (ICE) for induction treatment of younger newly diagnosed acute myeloid leukaemia patients (vol 131, pg 172, 2005)
    Russo, D
    Malagola, M
    de Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (06) : 804 - 804
  • [8] CLINICAL-PHARMACOLOGY OF INTERMEDIATE DOSE ARA-C (ID ARA-C) IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA IN RELAPSE
    VANPROOYEN, HC
    DEKKER, AW
    PUNT, K
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 60 (02) : 355 - 356
  • [9] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
  • [10] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Momparler, Richard L.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
12345